Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: October 5, 2007
Last updated: June 22, 2010
Last verified: June 2010

Primary objective: to demonstrate the non-inferiority of PCR adjusted adequate clinical and parasitological response at D28 of artesunate + amiodaquine versus artemether + lumefantrine, based on the first malaria attack of each subject.

Secondary objectives:

For the first attack: To compare the two groups of treatment in terms of:

  • D14 efficacy
  • Parasitological and fever clearance
  • Clinical and biological tolerability
  • Evolution of gametocyte carriage
  • Cardiac tolerability (QTc)

For the repeated attacks: To compare the two groups of treatment in terms of:

  • D14 and D28 clinical and parasitological effectiveness (PCR adjusted)
  • Clinical and biological tolerability
  • Proportion of patients without fever at D3
  • Proportion of patients without parasite at D3
  • Compliance
  • Impact on anaemia

During the total follow-up of the cohort: To compare the two groups of treatment in term of:

  • Treatment incidence density
  • Impact of repeated treatment on clinical and biological safety
  • Impact of repeated treatment on hearing capacity

Condition Intervention Phase
Drug: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
Drug: Coartem® (arthemether+ lumefantrine)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • PCR corrected and uncorrected clinical and parasitological cure rate [ Time Frame: at D28 and for the first attack ]

Secondary Outcome Measures:
  • PCR corrected and uncorrected clinical and parasitological cure rate [ Time Frame: at D28 and for the next attacks ]
  • Fever and parasitological clearance [ Time Frame: first attack ]
  • Proportion of afebrile patients and proportion of patients without parasites [ Time Frame: at D3 for the following attacks ]
  • Clinical tolerability (incidence and intensity of recorded AE) [ Time Frame: during the study period ]
  • Biological tolerability (Hb, bilirubin, ALAT, Creatinine, Leukocytes, Neutrophils and platelets count) [ Time Frame: during the study period ]
  • Cardiac tolerability (QTc) for the first attack in patients group aged >= 12 years) [ Time Frame: at the time of the first attack ]
  • Assessment and evolution of hearing function in patients groupe aged >=12 years [ Time Frame: during the study period ]

Enrollment: 366
Study Start Date: September 2007
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
Active Comparator: 2 Drug: Coartem® (arthemether+ lumefantrine)

Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.

Duration of treatment: 3 days


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Lists of Inclusion and Exclusion criteria:

Inclusion Criteria:

  • adults or children weighting more than 5 kg
  • axillary temperature >=37.5°C at D0 or history of fever within the previous 24hrs
  • confirmed Plasmodium falciparum monoinfection, with parasitemia>1000mcl
  • negative urinary pregnancy test for women of child bearing age before each new administration of treatment

Exclusion Criteria:

  • presence of any serious or clinical danger sign of malaria: prostration, consciousness disorders, recent and repeated convulsions, respiratory distress, inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice, haemorrhagic shock, systolic BP< 70 mmHg in adults or < 50 mmHg in children, spontaneous bleeding, inability to sit or stand
  • severe concomitant disease
  • allergy to one of the investigational drugs.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00540410

Sanofi-Aventis Administrative Office
Dakar, Senegal
Sponsors and Collaborators
Study Director: Valerie Lemeyre Sanofi
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00540410     History of Changes
Other Study ID Numbers: ARAMF_L_02873
Study First Received: October 5, 2007
Last Updated: June 22, 2010

Additional relevant MeSH terms:
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Artemether-lumefantrine combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Amebicides processed this record on April 27, 2017